The strong revenue growth and pipeline catalysts (KB803, KB801, KB407 data in 2H 2026) support a bullish outlook, but monitor pricing negotiations in Europe and upcoming clinical data readouts. Given historical stock underperformance post-earnings, consider taking profits on strength.
Price Chart
Executive Summary
Krystal Biotech reported strong Q1 2026 results with VYJUVEK revenue up 32% YoY to $116.4M and diluted EPS of $1.83, up 52.5% YoY. Pipeline advancements include complete enrollment for KB803 and on-track readouts for KB801 and KB407 in 2026.
Key Financial Metrics
Key Facts
- Q1 2026 VYJUVEK net product revenue of $116.4M, +32% YoY
- Diluted EPS of $1.83 vs $1.20 in Q1 2025
- Gross margin of 95% for Q1 2026
- Registrational studies for KB803 (DEB corneal abrasions) and KB801 (neurotrophic keratitis) on track for data readouts in 2026
- FDA granted platform technology designation for KB407 (CF) and KB111 (HHD)
- Cash and investments of $1.0 billion at quarter end
- FY2026 non-GAAP combined R&D and SG&A expense guidance of $175M-$195M
Financial Impact
Q1 revenue of $116.4M, net income of $55.9M, EPS of $1.83 diluted; significant beat vs prior year
Risk Factors
- Pricing and reimbursement negotiations in Germany, France, Italy, and Spain may delay international revenue growth
- Clinical trial risks for pipeline candidates (KB801, KB407, KB803)
- Competition from other gene therapies for DEB and other indications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286550 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | Insider Cluster | $351.26 $336.68 | ▲ +4.15% | ▲ +3.03% | $322.28 (+8.25%) |
Aug 14, 2026 7w ago | 144 | $335.73 $341.72 | ▲ +1.78% | ▲ +2.97% | $322.28 (−4.01%) |
Aug 3, 2026 8w ago | 8-K | $312.57 $331.59 | ▲ +6.08% | ▲ +4.06% | $322.28 (+3.11%) |
Jul 23, 2026 10w ago | Press Release | $335.19 $366.85 | ▲ +9.45% | ▲ +9.07% | $322.28 (−3.85%) |
Jun 5, 2026 17w ago | Insider Cluster | $301.76 $324.75 | ▲ +7.62% | ▲ +5.51% | $322.28 (+6.80%) |
May 4, 2026 21w ago | Press Release | $286.95 $312.88 | ▲ +9.04% | ▲ +6.10% | $322.28 (+12.31%) |
Apr 21, 2026 23w ago | Press Release | $272.66 $269.27 | ▼ −1.24% | ▼ −2.33% | $322.28 (+18.20%) |
Apr 3, 2026 26w ago | DEFA14A | $261.80 $267.41 | ▲ +2.14% | ▼ −1.99% | $322.28 (+23.10%) |
Feb 27, 2026 31w ago | Insider Cluster | $275.64 $253.69 | ▼ −7.96% | ▼ −5.98% | $322.28 (+16.92%) |
Feb 27, 2026 31w ago | Insider Cluster | $275.64 $253.69 | ▼ −7.96% | ▼ −5.98% | $322.28 (+16.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access